Equity · Healthcare
TBPH
NASDAQTheravance Biopharma (TBPH)
This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers.
- Market cap
- 879.5M USD
- P/E (TTM)
- 16.8
- Revenue, year to Dec 2025
- 107.5M USD
- EPS, diluted, year to Dec 2025
- 2.06 USD
- 52-week range
- 11 USD – 21 USD
- Avg volume
- 244.2K
as of Jul 17, 2026
Have Theravance Biopharma (TBPH) insiders bought or sold shares recently?
In the 90 days to 11 Nov 2026, Theravance Biopharma insiders reported 1 open-market sale and no purchases (SEC Form 4); the filings we hold, back to 11 Nov 2025, show no open-market purchase.
Form 4, 90 days to 11 Nov 2026, newest reported trade 15 Sep 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 15 Sep 2026 | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | Sell | 13,314 | 227K USD |
16 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 23 Sep 2026 | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | Other | 213,476 | |
| 23 Sep 2026 | GRAY SUSANNAHDirector | Other | 48,146 | |
| 23 Sep 2026 | Grimaud Brett A.SVP, GEN COUNSEL AND SECRETARY | Other | 355,168 | |
| 23 Sep 2026 | MITCHELL DEAN JDirector | Other | 97,213 | |
| 23 Sep 2026 | Miller AineSVP, DEV & HEAD OF IRE OFFICE | Other | 189,826 | |
| 23 Sep 2026 | O'Connor DonalDirector | Other | 80,213 | |
| 23 Sep 2026 | PAKIANATHAN DEEPIKADirector | Other | 64,074 | |
| 23 Sep 2026 | Sawaf AzizSVP & CHIEF FINANCIAL OFFICER | Other | 336,841 | |
| 23 Sep 2026 | Smaldone Alsup LaurieDirector | Other | 80,989 | |
| 23 Sep 2026 | Winningham Rick ECHIEF EXECUTIVE OFFICER | Other | 1,726,989 | |
| 23 Sep 2026 | Weiss Asset Management LP | Other | 7,457,060 | 126.8M USD |
| 20 Aug 2026 | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | Tax withheld | 5,667 | 96K USD |
Showing the 12 most recent of 16 compensation filings in this window. The figures above count all of them.
Which funds hold Theravance Biopharma (TBPH)?
9 of the 45 institutional funds we track reported a Theravance Biopharma position for the quarter ended 30 Jun 2026 — a combined 59.9M USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Two Sigma Investments | Held (±25%) | 1,225,587 | 20.8M USD | −2.6% |
| D. E. Shaw & Co. | Held (±25%) | 1,185,390 | 20.2M USD | +24.2% |
| Citadel Advisors | Added | 506,668 | 8.6M USD | +488.5% |
| Marshall Wace | Held (±25%) | 188,748 | 3.2M USD | +18.8% |
| Renaissance Technologies | Held (±25%) | 154,318 | 2.6M USD | +20.6% |
| Millennium Management | New position | 115,403 | 2.0M USD | |
| Tudor Investment Corp | Trimmed | 60,425 | 1.0M USD | −49.7% |
| AQR Capital Management | Added | 47,820 | 813K USD | +74.8% |
| Man Group | Held (±25%) | 40,613 | 690K USD | −3.5% |
Have members of Congress traded Theravance Biopharma (TBPH)?
The most recent congressional trade disclosed in Theravance Biopharma is a sale by George Whitesides (house, CA), dated 24 Mar 2025.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 24 Mar 2025 | George Whitesideshouse · Democrat–CA | Sale | 15K USD–50K USD | 30 days |
What has been filed or recorded for Theravance Biopharma (TBPH)?
The filings we hold for Theravance Biopharma, newest first: 3 quarterly earnings reports, 3 annual reports and 5 reported financial figures, the latest dated 30 Jun 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.11 USD | |
| 30 Jun 2026 | Financials | Total assets | 469.8M USD | at period end |
| 30 Jun 2026 | Financials | Total equity | 289.7M USD | at period end |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.10 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS 1.15 USD | |
| 31 Dec 2025 | Financials | Revenue | 107.5M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | 105.9M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | 2.06 USD | fiscal year |
| 30 Sep 2025 | Annual report | FY 2025 reported | EPS 0.07 USD | |
| 30 Jun 2025 | Annual report | FY 2025 reported | EPS 1.08 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.27 USD |
What do people ask about Theravance Biopharma (TBPH)?
What is Theravance Biopharma’s market cap?879.5M
Theravance Biopharma is worth 879.5M USD by market value as of 17 Jul 2026, which is the share price times the shares on issue from its SEC filings.
What is Theravance Biopharma’s P/E ratio?16.8
Theravance Biopharma has a price-to-earnings ratio of 16.8, as of 17 Jul 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.
What is Theravance Biopharma’s revenue?107.5M
Theravance Biopharma reported revenue of 107.5M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Theravance Biopharma insiders bought or sold shares recently?1 sale
In the 90 days to 11 Nov 2026, Theravance Biopharma insiders reported 1 open-market sale and no purchases (SEC Form 4); the filings we hold, back to 11 Nov 2025, show no open-market purchase. A further 16 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Theravance Biopharma?9 of 45
9 of the 45 funds we track reported a Theravance Biopharma position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Two Sigma Investments, D. E. Shaw & Co. and Citadel Advisors. See Funds
Have members of Congress traded Theravance Biopharma?1 trade
Yes. 1 trade in Theravance Biopharma appears in the congressional disclosures we hold: a sale by George Whitesides (House, CA) dated 24 Mar 2025, filed 23 Apr 2025. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did Theravance Biopharma last report earnings?−0.11
Theravance Biopharma last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −0.11 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close)
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- Wikimedia CommonsPortraits via Wikimedia Commons. George Whitesides: Ike Hayman, House Creative Services, Public domain.
- House disclosuresU.S. House of Representatives financial disclosures
- SEC EDGARXBRL company facts, latest period ended 30 Jun 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings